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Abstract
Protein phosphorylation tightly regulates specific binding of effector proteins that control many diverse biological functions
of cells (e. g. signaling, migration and proliferation). p140Cap is an adaptor protein, specifically expressed in brain, testis and
epithelial cells, that undergoes phosphorylation and tunes its interactions with other regulatory molecules via post-
translation modification. In this work, using mass spectrometry, we found that p140Cap is in vivo phosphorylated on
tyrosine (Y) within the peptide GEGLpYADPYGLLHEGR (from now on referred to as EGLYA) as well as on three serine
residues. Consistently, EGLYA has the highest score of in silico prediction of p140Cap phosphorylation. To further investigate
the p140Cap function, we performed site specific mutagenesis on tyrosines inserted in EGLYA and EPLYA, a second
sequence with the same highest score of phosphorylation. The mutant protein, in which both EPLYA/EGLYA tyrosines were
converted to phenylalanine, was no longer tyrosine phosphorylated, despite the presence of other tyrosine residues in
p140Cap sequence. Moreover, this mutant lost its ability to bind the C-terminal Src kinase (Csk), previously shown to
interact with p140Cap by Far Western analysis. In addition, we found that in vitro and in HEK-293 cells, the Abelson kinase is
the major kinase involved in p140Cap tyrosine phosphorylation on the EPLYA and EGLYA sequences. Overall, these data
represent an original attempt to in vivo characterise phosphorylated residues of p140Cap. Elucidating the function of
p140Cap will provide novel insights into its biological activity not only in normal cells, but also in tumors.
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Introduction
p140Cap encoded by the Srcin1 gene, is a docking protein
specifically expressed in brain, testis and epithelial cells [1–5]. So
far p140Cap has been mostly studied in epithelial tumor cells,
where it regulates integrin and growth factor-dependent carcino-
ma cell properties, involved in tumor progression [5–8]. In
addition p140Cap has been analyzed in neurons, where it can
control synapse formation/maintenance [1,3,4].
p140Cap is composed of a tyrosine-rich domain, two proline-
rich regions, a coil-coiled domain, two regions rich in charged
amino acids and a putative actin binding site [2]. Several of these
conserved domains have been already shown to associate with
specific partners. In particular p140Cap was originally identified
to bind through coil-coiled interactions to the synaptic membrane
protein SNAP-25 [1–5], and, through its second proline-rich
region, to Src kinase [6], Vinexin [3], and Cortactin [8].
Moreover, the C-terminal domain of p140Cap associates to
EB3, a member of the microtubule plus-end tracking protein EB
family [4].
p140Cap contains several serine and tyrosine residues, which
could undergo phosphorylation upon different biological stimuli.
Using large-scale phosphoproteomic studies ([9] and http://www.
phosphosite.org/), p140Cap phosphorylation sites have been
identified in distinct cell lines, but their role has not been
characterised. We have already shown that p140Cap is tyrosine
phosphorylated in epithelial cells upon integrin-mediated adhesion
and EGF treatment [2]. However, elucidating the functional
interplay between multiple p140Cap phosphorylated residues and
their role as binding sites remains a major challenge.
Csk and the Csk-homologous kinase (Chk) are endogenous
inhibitors constraining the activity of the Src-family kinases (SFKs)
in cells. Both kinases suppress SFKs by selectively phosphorylating
their consensus C-terminal regulatory tyrosine [10,11]. We have
previously shown that, upon cell-extracellular matrix adhesion or
EGF stimulation, p140Cap activates Csk. This kinase phosphor-
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ylates an inhibitory tyrosine on the C-terminal domain of Src
allowing the closure of Src in an inactive conformation [6].
Although we have already shown that Csk directly interacts with
p140Cap [6], the nature of this interaction has not been fully
elucidated.
Mass spectrometry (MS)-based proteomics has been widely used
for studies of protein phosphorylation [12]. It has been signifi-
cantly improved by phosphorylation-directed multistage tandem
MS (pdMS3) using liquid chromatographic separation (LC) and
hybrid linear ion trap (LTQ)-FT mass spectrometers [13]. This
approach allows the accurate measurement of parent ion masses,
by a Fourier transform ion cyclotron resonance (FTICR) ‘‘selected
ion monitoring’’ (SIM) scan, and the detection of diagnostic
neutral loss of phosphoric acid (98 Da). This diagnostic loss from
the precursor ion, detected in a MS2 mode automatically triggered
data-dependent MS3 fragmentation of the precursor ion. This
results in high yield of peptide backbone fragments, determining a
high confidence peptide identification and phosphorylation site
assignment [14].
Here we applied pdMS3-based analytical strategy targeted
toward the detection and sequencing of in vivo phosphopeptides
derived from p140Cap and we identified one phosphotyrosine and
three phosphoserine residues. By site directed mutagenesis we
defined the tyrosines contained in the sequences EGLYA and
EPLYA as the major residues responsible for p140Cap tyrosine
phosphorylation and functionally validated their essential role in
binding to the Csk kinase. Moreover, we found that in vitro an in
Human Embryonic Kidney (HEK)-293 cells, the Abelson (Abl)
kinase is the major tyrosine kinase able to trigger p140Cap
phosphorylation on these motifs.
Materials and Methods
Cell Lines, Reagents, Antibodies
Human embryonic kidney HEK-293 and human breast cancer
MCF7 cells were obtained from ATCC and cultured in DMEM
with 10% FCS and Penicillin/Streptomycin. p140Cap monoclo-
nal and polyclonal antibodies were produced in our laboratory as
previously described in [2]. Antibodies to Src, Vinculin, Csk, and
phosphotyrosine PY99 were from Santa Cruz Biotechnology
(Santa Cruz, CA), to GST from BD Bioscience (2350 Qume Drive
San Jose, CA 95131), and to Tubulin from SIGMA, to
Glutathione-Sepharose, Protein A-Sepharose, Protein G-Sephar-
ose, Horse radish peroxidase, nitrocellulose and films were from
GE Healthcare Bio-Science AB. Tissue culture media, serum and
antibiotics were from Invitrogen. Src kinase specific inhibitor
SU6656 was obtained from SIGMA. Abl kinase specific inhibitor
(Imatinib) was a kind gift of Dr. Giuseppe Saglio (University of
Torino).
Mass Spectrometry
Nanoscale liquid chromatography mass spectrometry experi-
ments were performed on an Agilent 1100 nanoflow system
(Agilent Technologies) coupled a 7-tesla Finnigan LTQ-FT mass
spectrometer (Thermo Electron, Bremen, Germany) equipped
with a nanoelectrospray ion source (Proxeon Biosystems, Odense,
Denmark) as described previously [14]. The following instrumen-
tal conditions were used: spray voltage, 2.4 kV; no sheath and
auxiliary gas flow; ion transfer tube temperature, 100uC; collision
gas pressure, 1.3 millitorrs. A data-dependent mode allowed the
LTQ-FT mass spectrometer to automatically switch between MS,
MS2, and neutral loss-dependent MS3 acquisition. Survey full scan
MS spectra were acquired between m/z 300 Th and 1600 Th by
FTICR with resolution r 25000 at m/z 400. Then, the three most
intense ions of each survey full scan MS spectrum were
sequentially isolated for accurate mass measurements by a FTICR
‘‘selected ion monitoring’’ (SIM) scan. These ions were also
fragmented in the linear ion trap using collision-induced
dissociation. Data-dependent settings were enabled to trigger a
MS3 scan when a neutral loss of 97.99, 48.99 or 32.66 Da (singly,
doubly and triply charged phosphopeptides) was detected among
the 10 most intense fragment ions of the MS2 spectra.
Database Searching
MSn data were processed (smoothing, background subtraction,
and centroiding) using the program DTASuperCharge (Source-
Forge, Inc.). The processed files were subsequently searched
against the human sequence library in the International Protein
Index (IPI) and UniProtKB/Swiss-Prot protein sequence databas-
es using an in-house Mascot server (Matrix Science Ltd.,London,
UK). The databases searches were performed choosing trypsin as
enzyme and one miss cleavage was allowed. Carbamidomethyl
(Cys) was considered as the fixed modification. Oxidation (Met),
N-acetylation (protein) and phosphorylation (STY) were chosen as
variable modifications. The data were searched with a peptide
mass tolerance of 630 ppm and a fragment mass tolerance of
60.6 Da.
cDNA Constructs and Site Specific Mutagenesis of
p140Cap
pEGFP-N1-p140Cap cDNA [2] was used to generate single,
double or triple point mutation of p140Cap tyrosines into
phenylalanine (Y/F) following manufacture instruction of Quick-
change Lightening Mutagenesis kit (Agilent Technologies, Inc.Life
Sciences and Chemical Analysis Group Santa Clara, CA 95051-
7201USA), and using the primers:
EPLY/FA F 59GAAG-
GAGCCGTTGTTTGCTGCTTTTCCTGGC
EPLY/FA R 59GCCAGGAAAAGCAGCAAA-
CAACGGCTCCTTC
EGLY/FA F 59GGGCGAGGGCCTCTTTGCCGATCCC-
TACGGG
EGLY/FA R 59CCCGTAGGGATCGGCAAA-
GAGGCCCTCGCCC
FY/FELE F 59GCTCGCAATGTCTTCTTCGAGCTG-
GAAGACGTC
FY/FELE R 59GACGTCTTCCAGCTCGAAGAAGA-
CATTGCGAGC
DPY/FG F 59TGCCGATCCCTTCGGGCTGCTGCAC-
GAGG
DPY/FG R 59CCTCGTGCAGCAGCCCGAAGG-
GATCGGCA.
pcDNA3-BCR-Abl coding for the active form of Abl [15] was a
kind gift of Prof. G. Saglio, University of Torino.
Production of Recombinant Csk Mutants
Csk full length was cloned into pQE vector by amplification of
I.M.A.G.E. full Length cDNA clone IRAVp968G01111D, using
specific primers. The Csk SH3 (37–182 bp from ATG) and SH2
(239–513 bp from ATG) domains were amplified by Csk full
length using specific primers, and the amplification products were
cloned into pGEX 4T3 vector using BamHI and EcoRI restriction
enzymes. Csk Delta SH2 was originated by cloning in the pQE
vector two fragments, one amplified from 1 to 239 bp with BamHI
and XbaI restriction sites at the end, and the other amplified from
513 to the stop codon with XbaI and HindIII restriction sites at
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the end. Recombinant fusion proteins were produced in E. coli as
described [2].
Far Western
Far-Western analysis was performed as described in [6]. Briefly,
membranes were blocked for 1 h in TBS, 0.1% Tween-20, 5%
BSA and incubated for 3 h with 1 microgram/ml of different Csk
recombinant proteins. Filters were first decorated with anti-Csk or
anti GST antibody and subsequently with anti-p140Cap.
Biochemical Analysis of p140Cap Tyrosine
Phosphorylation
To analyze phosphorylation of p140Cap (NCBI Reference
Sequence: NP_079524.2; REFSEQ: accession NM_025248.2) and
of its mutants, HEK-293 cells were transiently transfected with the
corresponding cDNAs by conventional calcium phosphate pre-
cipitation protocols. 48 hrs after transfection, cells were extracted
with lysis buffer (50 mM HEPES (pH 7.5), 150 mM NaCl,
1.5 mM MgCl2, 1 mM EDTA, 1% Triton X-100, and 10%
glycerol) containing protease and phosphatase inhibitors (1 mM
PMSF, 10 microgram/ml leupeptin, 10 microgram/ml aprotinin,
10 mM NaF, and 1 mM Na3VO4). In some experiments cells
were treated for 5 minutes with 100 micromolar of Pervanadate
Stock solution (30 mM of Sodium ortovanadate and 0,18%
Hydrogen peroxide diluted in PBS 1X) or starved overnight and
stimulated with 20% Fetal Bovine Serum (FBS) for 30 min. In
specific experiments cells were transfected with p140Cap and its
mutant together with the pcDNA-3-BCR-Abl construct. Cell
extracts were centrifuged at 13,0006g for 10 minutes, and the
supernatants were collected and assayed for protein concentration
using the Bio-Rad protein assay method (Bio-Rad). For immuno-
precipitation, Dynabeads (Invitrogen) were cross linked with the
specific p140Cap monoclonal antibody, following manufacture
protocol. Cell extracts were incubated with the Dynabeads-
conjugated antibody overnight at 4uC. The immunoprecipitates
were washed three times with 1 ml of lysis buffer, resolved on
SDS-PAGE, transferred onto nitrocellulose and reacted with
specific antibodies. As input, fifty micrograms of cell extracts were
analysed by SDS-PAGE and Western Blotting.
Identification of Tyrosine Kinase Activity on Synthetic
EPLYA and EGLYA Peptides
This assay was performed by ProQinase (Freiburg, GER-
MANY). The phosphorylation profile of two biotinylated sample
peptides, SIIKIYRKEPLYAAFPGSHLTNGDL and LAG-
KAGGMVLVKGEGLYADPYGLLH, synthesized by JPT Pep-
tide Technologies (Berlin, Germany) was determined at three
concentrations each (1, 0.5, 0.25 micromolar) in triplicate in a
radiometric activity assay based on streptavidin-coated FlashPla-
teTM Plus, using three recombinant protein kinases, Abl, Alk and
Src, respectively.
The reaction cocktails were pipetted into 96 well, V-shaped
polypropylene microtiter plates (‘‘assay plates’’) in the following
order: 10 microliters of kinase solution, 40 microliters of buffer/
ATP/test sample mixture. The reaction cocktails contained
60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2,
3 micromolar Na3VO4, 1.2 mM DTT, 50 microgram/ml
PEG20000, 1 micromolar ATP/[gamma P33]-ATP
(8.061005 cpm per well), protein kinase and sample peptide (1/
0.5/0.25 micromolar). The assay plates were incubated at 30uC
for 60 minutes. Subsequently, the reaction cocktails were stopped
with 20 microliters of 4.7 M NaCl/35 mM EDTA. The reaction
cocktails were transferred into 96-well streptavidin-coated Flash-
PlateTM Plus (PerkinElmer, Boston, MA, USA), followed by
30 min incubation at room temperature on a shaker. Subsequently
the plates were aspirated and washed three times with 250
microliters of 0.9% NaCl. Kinase activity dependant transfer of
P33 (‘‘counting of cpm’’) was determined with a microplate
scintillation counter (Microbeta, Perkin Elmer).
Results
In vivo Mapping of p140Cap Phosphorylation Sites
p140Cap docking protein includes a number of serine and
tyrosine residues (Figure 1A) that upon phosphorylation could
serve as binding sites for other proteins. We used pdMS3 approach
to detect the in vivo phosphorylation of p140Cap in human breast
cancer cells. p140Cap was purified from extracts of MCF7 cells by
immunoprecipitation with specific monoclonal antibodies against
p140Cap, and subjected to tryptic digestion. The MS and
computational analyses confirmed that the protein recovered from
the SDS-PAGE gel band contained only the p140Cap protein.
They also revealed four singly phosphorylated peptides with
masses 1208.5540, 1580.7613, 1593.7919 and 1825.9329 Da
(Table 1).
Manual interpretation of the MS2 and MS3 spectra allowed us
to confidently allocate the position of the phosphorylated sites of
p140Cap. The MS2 spectrum of the peptide with mass
1825.8036 Da [mass/charges (m/z): 913.9091 Th, charges (z):
2+] showed an extensive peptide backbone fragmentation,
allowing a high-confidence phosphorylation assignment
(Figure 1B). In particular, amino-terminal b5, b6, b7 and b8 ions
indicated that the phosphorylation was located on tyrosine-396.
Furthermore, carboxyl terminal y-ions (i.e. y3, y4, y5, y6, y7, y8, y9,
y10, y11 ions) did not contain a phosphoryl group and ruled out the
possibility of phosphotyrosine-400. Therefore, the in vivo mapping
revealed the presence of a tyrosine phosphorylated residue,
inserted in the sequence 392-GEGLpYADPYGLLHEGR-407
(briefly indicated as EGLYA) (Table 1, and Figure 1B). Interest-
ingly the tyrosine included in the EGLYA sequence has also been
found phosphorylated by a large-scale identification of tyrosine
phosphorylation sites from murine brain [16].
In MS2 spectrum the peptide with mass 1208.5540 Da, (m/z:
605.2843 Th, z: 2+) lost 48.9975 Th generating an ion (m/z:
556.2868 Th, z: 2+) which was subjected to MS3 analysis
(Figure 1C). The fragmentation pattern showed that serine-987
was phosphorylated (i.e. RGpSDELTVPR). The peptide 43-
RFpSNVGLVHTSER-55 (mass: 1580.7614 Da; m/z:
527.9277 Th, z: 3+) was subjected to MS2 and MS3 fragmentation
(Figure 1D), indicating that serine-45 was phosphorylated
(Figure 1D). The MS2 spectrum of the peptide 997-
TEKPSKpSPPPPPPR-1010, whose mass is 1593.7919 Da (m/z
532.2713 Th, z: 3+), is shown in Figure 1E. The presence of
phosphorylated b7 ion (indicated as b*7) and of y8, which lost
phosphoric acid (yDelta8) suggested the presence of the phosphor-
ylated serine-1003. The b2, b4, b6 ions are not modified, excluding
the presence of a phosphoryl group on threonine-997 or serine-
1001. Overall, three peptides contained phosphorylated serine
residues (Figure 1C–E), namely RGpSDELTVPR,
RFpSNVGLVHTSER, and TEKPSKpSPPPPPPR were identi-
fied. Among them, serine S45 and S987 are conserved among
human and mouse p140Cap sequences, and have been previously
identified in murine phosphoproteomic screens (http://www.
uniprot.org/uniprot/Q9QWI6), underlying the relevance of
phosphorylation of these sites across the species.
In human breast cancer cells p140Cap undergoes in vivo
phosphorylation on multiple sites, specifically identified in one
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Figure 1. Amino acid sequence of p140Cap and spectra of in vivo phosphorylated peptides. A. Amino acid sequence of p140Cap (NCBI
Reference Sequence: NP_079524.2; REFSEQ: accession NM_025248.2) showing, the peptides found to be phosphorylated by MS analysis
(phosphoserine: blank open box; phosphotyrosine: grey box) and the EPIYA-like motifs (underlined). All the tyrosine residues present in p140Cap are
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tyrosine and three serine residues. Since we have shown that
integrin-mediated adhesion or serum treatment induce p140Cap
tyrosine phosphorylation [2] we focused our attention on tyrosine
residues to evaluate the function of Y396 in the p140Cap protein.
p140Cap Tyrosine Phosphorylation Relies on Two Major
Tyrosine Residues Included in the Sequences EGLYA and
EPLYA
Since we have already demonstrated that p140Cap directly
binds to Csk [6], we were interested in assessing the relevance of
tyrosine phosphorylation of the EGLYA motif in Csk binding.
Interestingly, p140Cap also contains a sequence analogous to
EGLYA, represented by the EPLYA motif (see Figure 1A). These
two sequences are similar to the EPIYA motif, previously found in
the bacterial CagA protein involved in Helicobacter Pylori
pathogenesis [17–20], and in the mammalian Pragmin/SgK223
[21]. Upon tyrosine phosphorylation at the EPIYA motif, these
proteins acquire the ability to interact with the SH2 domain of
Csk.
We closely examined our liquid chromatography data in order
to find evidence of the in vivo Y264 phosphorylation in MCF7
cells. The non-phosphorylated form of the peptide 261-
EPLYAAFPGSHLTNGDLR-278 was automatically subjected to
MS/MS fragmentation. This peptide (mass: 1956.96 Da) was
detected as 3+ (m/z: 653.33), at retention time (RT) 30.17 min
(data not shown). Thanking into account these features, we
calculated a possible mass of the 261–278 phosphorylated form
(2036.93 Da). In a chromatogram at RT 30.46 min, there was
peak at m/z 679.99, (z: 3+), indicating a mass of 2036.93. This
could correspond to the phosphorylated 261–278 peptide, but it
was not selected for MS/MS fragmentation. In other runs we did
not find the 679.99 peak suggesting that the tyrosine 264 residue
(EPLYA) can be phosphorylated in a very dynamic way whose
kinetics is different from the tyrosine 396 (EGLYA) in human
breast cancer MCF7 cells (data not shown).
Taking into account our in vivo data, we used the NetPhos
program to predict the score of putative phosphorylation by
tyrosine kinases [22]. The EGLYA and EPLYA tyrosines showed
the highest probability score (0.981 and 0.980, respectively,
Table 2), leading us to perform site-specific mutagenesis to
convert these two tyrosines to phenylalanine. We also selected two
low score tyrosines, one inserted in the peptide GEGLpYAD-
PYGLLHEGR (ADPYG) and the other in the peptide
RNVFYELED (FYELE) as negative internal controls (Figure 2A).
Wild type p140Cap (WT) and the mutant cDNAs were
transiently transfected in Human Embryonic Kidney 293 (HEK-
293) cells. Within 48 hours upon transfection, cells were treated
with 100 micromolar pervanadate solution for 5 minutes to
significantly inhibit phosphatase action and enhance tyrosine
phosphorylation. p140Cap and its mutants were then immuno-
precipitated and analysed for tyrosine phosphorylation by blotting
with antibodies to phosphorylated tyrosines. In cells expressing the
single tyrosine mutant EPLY/FA or EGLY/FA, p140Cap
tyrosine phosphorylation was decreased compared to WT,
indicating that both tyrosine residues contribute to p140Cap
phosphorylation. Strikingly, the double mutant (EPLY/FA,
EGLY/FA) was completely defective in phosphorylation
(Figure 2B). In contrast, the single mutants on FY/FELE or
ADPY/FG (not shown) and the double mutant (FY/FELE,
ADPY/FG) were still phosphorylated on tyrosine at a similar
extent of the WT (Figure 2B). Therefore, the tyrosines inserted in
the sequences EPLYA and EGLYA are the major p140Cap
phosphorylated sites.
p140Cap and Csk Directly Associate through the SH2
Domain of Csk
Our previous results showed that p140Cap can directly interact
with the Csk protein by Far western analysis [6]. In addition to its
catalytic domain, Csk contains both a SH2 and a SH3 domain
(Figure 3A). To assess how Csk can mediate binding to p140Cap,
bacterial recombinant GST fusion proteins expressing Csk SH2 or
SH3 domains, were produced. Moreover, a bacterial fusion
protein expressing a Csk mutant deleted of the SH2 domain (Csk
DeltaSH2) was also generated (Figure 3B). HEK-293 cells were
transiently transfected with p140Cap cDNA and within 48 hours
upon transfection p140Cap was immunoprecipitated, run on a
SDS-PAGE and subjected to Far Western blotting by incubation
with Csk recombinant mutant proteins. Figure 3C shows that only
the Csk SH2 domain was able to bind p140Cap, while the Csk
DeltaSH2 mutant did not associate. Consistently, the SH3 domain
of Csk was not able to bind p140Cap (Figure 3C). Overall these
results indicate that p140Cap and Csk directly interact through the
SH2 domain of Csk.
The EPLYA and EGLYA Tyrosines Mediate
Phosphorylation-dependent Csk Binding to p140Cap
Tyrosine phosphorylation at the EPIYA-like motif allows the
protein CagA and Pragmin/Sgk223 to interact with the SH2
domain of Csk [20,21]. To assess the relevance of EPLYA and
EGLYA phosphorylated tyrosines to p140Cap-Csk interaction,
transiently transfected HEK-293 cells were treated with 100
indicated in Bold. Note that the phosphoserines in position 45, 987 and 1003 are conserved among human and murine sequences. B. The
phosphopeptide 392-GEGLpYADPYGLLHEGR-407 with m/z 913.9091 (z: +2) was sequenced by LC-MS2. The signals of ions within 350–1030 and 1100–
1685 m/z were enhanced of 2 and 5 times, respectively. The signal enhancement facilitated the labeling of the ions. Only the most relevant fragment
ion signals are labeled in the MS2 spectrum. *, Ions containing phosphorylated tyrosine-396 (pY396). C. MS3 spectrum of the phosphopeptide 985-
RGpSDELTVPR-994. In MS2 mode the parent ion at m/z 605.2843 Th (z: 2+) lost phosphoric acid generating an ion at m/z 556.2868 Th, which was
subjected to MS3 fragmentation. Delta indicates the loss of phosphoric acid. D. MS3 spectrum of the peptide 43-RFpSNVGLVHTSER-55. E. MS2
spectrum of 997-TEKPSKpSPPPPPPR-1010. *, Ions containing phosphorylated serine-1003 (pS1003). PPP-CO indicates an internal fragment ion
containing three proline residues which has lost carbon monoxide (28 Da).
doi:10.1371/journal.pone.0054931.g001
Table 1. Phosphopeptides of p140Cap protein.
M (Da) p140Cap phosphopeptides sequence
Ser 45 1580.7613 43-RFpSNVGLVHTSER-55
Ser 987 1208.5540 985-RGpSDELTVPR-994
Ser 1003 1593.7919 997-TEKPSKpSPPPPPPR-1010
Tyr 396 1825.9329 392-GEGLpYADPYGLLHEGR-407
In vivo phosphorylated p140Cap was immunoprecipitated from MCF7 human
breast cancer cells and four phosphopeptides were recovered by liquid
chromatography, analysed by mass spectrometry (MS) and subjected to MS2
and MS3 fragmentation. We indicate the position of phosphorylation sites
within the NCBI Reference sequence NM_025248.2, the masses of the peptides
(expressed in Da) and their amino acidic sequence.
doi:10.1371/journal.pone.0054931.t001
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micromolar pervanadate solution for 5 minutes. The presence of
Csk was evaluated in the immunoprecipitates of WT and p140Cap
mutants by western blot. As shown in Figure 4A, while Csk was
detected in the immunoprecipitate obtained from WT transfected
cells, it was absent in those deriving from the extracts of cells
transfected with the double p140Cap mutant (EPLY/FA, EGLY/
FA), indicating that these two phosphorylated tyrosines mediate
Csk binding.
To further investigate p140Cap-Csk binding upon tyrosine
phosphorylation induced by a physiological stimulus, starved cells
were treated with 20% FBS for different times. As shown in
Figure 4B, p140Cap tyrosine phosphorylation was induced over a
basal level within 15 minutes of FBS treatment, with a parallel
increase in Csk binding (left panels). In cells transfected with the
EPLY/FA, EGLY/FA double mutant, upon FBS treatment,
p140Cap tyrosine phosphorylation did not increase over the basal
level that was already much lower than that of p140Cap WT. In
these conditions Csk was not detectable in p140Cap EPLY/FA,
EGLY/FA double mutant immunoprecipitates (Figure 4B, right
panels). Accordingly, while Src kinase activity, reported as
phosphorylation of Y416, was inhibited in cells expressing
p140Cap WT; it was partially rescued by over-expression of the
EPLY/FA, EGLY/FA double mutant (Supplementary Figure S1).
In summary, Csk associates only to tyrosine phosphorylated
p140Cap and upon phosphorylation the tyrosine residues EPLYA
and EGLYA mediate the binding to Csk, resulting in inhibition of
Src kinase activity.
p140Cap is a Substrate of the Abelson Tyrosine Kinase
In order to identify the tyrosine kinases involved in phosphor-
ylation of the EPLYA and EGLYA sequences, we first performed
in silico analysis. Based on the fact that three different tyrosine
kinases, namely Abl, Alk, and Src displayed the highest scores
(data not shown), we took advantage of the KinaseFinder service
package (see Materials and Methods) to find out whether the
EPLYA and EGLYA peptides could function as substrates for
these three recombinant protein tyrosine kinases in an in vitro
system. As shown in Figure 5A, when different amounts of the
synthetic peptide SIIKIYRKEPLYAAFPGSHLTNGDL includ-
Figure 2. p140Cap tyrosine phosphorylation depends mainly on two tyrosine residues. A. Schematic representation of p140Cap structure
and localization of FYELE, EPLYA, EGLYA, and ADPYG sequences into the tyrosine rich region. These four tyrosine residues have been mutated to
phenylalanine. B. cDNAs encoding GFP, GFP-p140Cap full length (p140 WT) and its single (p140 EPLY/FA, p140 EGLY/FA), double (p140 EPLY/FA,
EGLY/FA; p140 FY/FELE, ADPY/FG) and triple (p140 EPLY/FA, EGLY/FA, ADPY/FG) mutants were used to transfect HEK-293 cells. 48 hours after
transfection cells were treated for 5 minutes with 100 micromolar pervanadate solution. Cell extracts were immunoprecipitated with a specific
antibody to p140Cap and immunocomplexes were analysed by western blotting using monoclonal antibodies to phosphotyrosine (PY99), p140Cap
and Tubulin respectively. The results are representative of six independent experiments.
doi:10.1371/journal.pone.0054931.g002
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ing the EPLYA sequence, were incubated with recombinant
purified kinases, only the Abl kinase was able to significantly
trigger peptide phosphorylation at both 0,5 and 1 micromolar
substrate concentrations. On the other hand, both Abl and Alk
kinases were able to phosphorylate the synthetic peptide
LAGKAGGMVLVKGEGLYADPYGLLH, including the
EGLYA sequence, although with low efficiency, at the high
substrate concentration (1 micromolar) (Figure 5B). Since Src
kinase was almost inactive in these in vitro assays and the ALK
kinase is not expressed in HEK-293 cells (data not shown), we
focused our analysis on the ability of Abl to trigger p140Cap
tyrosine phosphorylation in these cells.
Abl tyrosine kinase is involved in many key cellular processes
such as cytoskeleton remodelling, cell shape and movement,
through phosphorylation of specific substrates including many
adaptor proteins [23,24]. Notably, interfering with Abl kinase
activity by treating HEK-293 cells with 10 micromolar Imatinib, a
specific Abl inhibitor [25], resulted in a consistent loss of p140Cap
tyrosine phosphorylation (Figure 5C). As already suggested by the
in vitro kinase assays, the use of Src inhibitor SU6656 did not affect
p140Cap tyrosine phosphorylation (Figure 5C). To further
assessing the relevance of Abl in p140Cap phosphorylation,
HEK-293 cells were transfected with both p140Cap WT and
shRNA for Abl silencing (shG10), resulting in down-regulation of
Abl expression of about 40%. Upon Abl silencing, p140Cap
tyrosine phosphorylation was reduced in a corresponding manner
(Supplementary Figure S2). Moreover HEK-293 cells were
transiently co-transfected with either p140Cap WT or the double
mutant (EPLY/FA, EGLY/FA) together with the constitutive
active form of Abl, namely BCR-Abl [25]. The expression of the
active BCR-Abl induced p140Cap WT tyrosine phosphorylation
(Figure 5D, left panel), at a significantly higher level of that
induced upon cell treatment with 100 micromolar pervanadate
solution (Figure 5D, right panel). Remarkably, the p140Cap
double mutant (EPLY/FA, EGLY/FA) was poorly phosphory-
lated by active BCR-Abl (Figure 5D, left panel). Taken together,
these data demonstrate that both in in vitro kinase assays and in
HEK293 cells, p140Cap undergoes tyrosine phosphorylation on
the EPLYA and EGLYA sequences preferentially through Abl
kinase activity.
Discussion
In this study we provide evidences of p140Cap in vivo
phosphorylation on one tyrosine and three serine residues in
MCF7 breast cancer cells. The in vivo tyrosine phosphorylation
detected on the EGLYA sequence was validated by site specific
mutagenesis, showing that this tyrosine, together with that
embedded in the sequence EPLYA, represent the major residues
involved in p140Cap phosphorylation. Moreover the EPLYA and
EGLYA motifs are also responsible for the interaction between
phosphorylated p140Cap and the Csk kinase. Furthermore, we
identify Abl as the major tyrosine kinase that can trigger p140Cap
phosphorylation on these sequences. Overall these data represent
the first attempt to decipher the function of p140Cap post-
translational modification, mostly tyrosine phosphorylation, the
structural basis of p140Cap-Csk interaction, and one major
tyrosine kinase involved in p140Cap phosphorylation.
Phosphorylation on specific amino acid residues leads to
conformational changes that modulate and control intrinsic
biological activity, sub cellular location, stability, and interaction
with other proteins. p140Cap contains many residues that upon
phosphorylation could promote protein–protein interactions,
leading to the assembly of signalling complexes [5]. Here we
show that indeed p140Cap is phosphorylated in vivo on three
serine residues that are highly conserved and distributed over the
entire length of the p140Cap protein. In particular a serine
phosphorylated peptide RFpSNVGLVHTSER lies in the N-
terminal domain of the protein, while the RGpSDELTVPR and
TEKPSKpSPPPPPPR sequences are located in the most C-
terminal part, namely in the second proline rich region of
p140Cap. Interestingly, p140Cap has already been shown to be
phosphorylated on the serine RGpSDELTVPR in a global
phospho-proteomic analysis of human and mouse brain extracts
[2,26,27], suggesting that this serine might play a key role in
p140Cap biology. Site specific mutagenesis and the identification
of putative binding modules for these phosphorylated serine
residues will offer new paradigms for understanding how cell
signalling can be regulated by p140Cap serine phosphorylation.
The tyrosine embedded in the EGLYA sequence (GEGL-
pYADPYGLLHEGR) is phosphorylated in vivo and has the
highest score of phosphorylation prediction (0.981), based on the
use of the NetPhos algorithm [22] indicating that in silico data
match accurately with the in vivo analysis. Moreover, this tyrosine
residue has also been identified as phosphorylated by a global
phosphoproteomic analysis of murine brain [16]. Interestingly,
among the 24 tyrosines present in the p140Cap sequence, only
another residue, the tyrosine included in the 261–278 peptide
(namely EPLYA), showed a similar level of phosphorylation during
Table 2. Prediction of tyrosine phosphorylation and relative
score.
Pos Context Score
24 DDAEYPREY 0.572
28 YPREYRTLG 0.104
91 LKSKYPQHA 0.696
111 EQPNYWSFK 0.884
138 AKLSYASAE 0.818
241 RNVFYELED 0.220
258 IIKIYRKEP 0.008
264 KEPLYAAFP 0.980
283 REMVYASRE 0.523
332 SRLSYAGGR 0.235
340 RPPSYAGSP 0.875
396 GEGLYADPY 0.981
400 ADPYGLLH 0.400
420 DPFAYPGAG 0.137
427 AGGLYKRGS 0.206
438 SLSTYSAAA 0.379
452 EDSLYKAAG 0.952
462 GGPLYGDGY 0.683
466 GDGYGFRL 0.488
495 PHSPYSGPP 0.353
722 ERLRYLNDE 0.342
995 TVPRYRTEK 0.049
1131 QRAEYMRIQ 0.339
The human p140Cap protein was analysed with the NetPhos algorithm [22] to
obtain a score of putative phosphorylation for each of the 24 tyrosines present
in the sequence. Pos. indicates the first tyrosine position in the human p140Cap
protein. Context identifies the amino acid sequence surrounding each tyrosine.
doi:10.1371/journal.pone.0054931.t002
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an in silico prediction (0.980), leading us to analyse the relevance of
both residues by site specific mutagenesis. The observation that
p140Cap mutated in EPLYA or EGLYA is still phosphorylated on
tyrosine even though at a low level, suggests that each of these two
tyrosines can be independently phosphorylated. Moreover, the fact
that the double mutant in EPLYA and EGLYA is no longer
phosphorylated, demonstrates that these two tyrosines are the
most relevant in determining p140Cap tyrosine phosphorylation.
Regarding the dynamics of the EPLYA modification in human
breast cancer MCF7 cells, liquid chromatography data indicated
that the tyrosine 264 residue (EPLYA) could be in-vivo
phosphorylated in a very dynamic way, with a kinetics different
from the tyrosine 396 (EGLYA).
Notably, the tyrosine residues in the sequence FYELE and in
the sequence ADPYG - which is very close to the EGLYA and
included in the in vivo phosphorylated GEGLpYADPYGLL-
HEGR - do not account for p140Cap phosphorylation. Indeed,
while both EGLYA and EPLYA have been both found
phosphorylated in human breast cancer cells (http://www.
phosphosite.org/), FYELE and ADPYG were not found phos-
phorylated in human samples. Overall, these results represent the
first characterisation of the most significant p140Cap phosphotyr-
osines in the human setting.
Csk kinase is a potent negative regulator of Src, due to its ability
to phosphorylate the negative regulatory tyrosine 527 on the C-
terminal domain of Src [28]. Our previous data have already
demonstrated that upon adhesion to fibronectin, p140Cap up-
regulates Csk activity, leading to increased phosphorylation of Src
on tyrosine 527. Moreover, we have also proved that the Csk
interacts with p140Cap by Far Western analysis [6]. In this study
we show that p140Cap directly interacts with Csk SH2 domain,
and that the tyrosine phosphorylation of p140Cap modulates its
binding to Csk. Moreover, we identify the phosphorylation of the
EGLYA and EPLYA tyrosines as the most relevant for Csk
association, either upon pervanadate treatment or physiological
FBS stimulus. Taken together, our data imply that the functional
Figure 3. p140Cap binds directly to Csk through Csk SH2 domain. A. A schematic representation of full length Csk kinase protein domains.
B. A schematic representation of different Csk recombinant mutant proteins. C. HEK-293 cells transfected with GFP or GFP-p140Cap full length (p140
WT) were treated with 100 micromolar pervanadate solution as in Figure 2B. Cell extracts were immunoprecipitated with a specific antibody to
p140Cap or a pre immune serum as negative control (Ctrl). Immunocomplexes run on 6% SDS-PAGE and transferred to nitrocellulose, were analysed
by Far western blotting, incubating with the different Csk recombinant proteins and probing with antibodies specific for GST, Csk and p140Cap. The
results are representative of three independent experiments.
doi:10.1371/journal.pone.0054931.g003
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interaction between p140Cap and Csk relies on the ability of
phosphorylated tyrosine embedded in EGLYA and EPLYA to
associate Csk. Moreover, the two sequences EGLYA and EPLYA
are similar to the EPIYA motif, that has been found in CagA, an
effector protein involved in Helicobacter Pylori pathogenesis [17–
20]. The bacterial CagA protein contains several (from one to five)
repeated EPIYA or EPIYA-like sequences that, upon delivery into
mammalian cells, undergo tyrosine phosphorylation, leading to
pathogenesis through the formation of complexes with SH2
domain-containing proteins. Remarkably, in Helicobacter pylori
the CagA EPIYA sequence is involved in binding of Csk SH2
domain, resulting in Csk membrane recruitment with subsequent
inhibition of SFKs [19,20]. Interestingly, the EPIYA motif has
similar functions in the mammalian Pragmin/SgK223 protein, as
a module able to interact with the Csk SH2 domain. An elevated
SFK activity is detected in cells expressing Pragmin, collectively
indicating that this protein provokes cell morphological transfor-
mation by sequestering Csk and potentiating SFK kinase activity
[21]. Thus, expression of proteins like Pragmin or p140Cap that
contain EPIYA-like motifs could interfere with Csk activation [28]
and/or localisation [21], finely tuning SFK activity inside the cells.
We have shown here that the EPLYA and the EGLYA
sequences are relevant for both vanadate- and serum-dependent
phosphorylation, indicating that these tyrosine residues might be
substrate of several tyrosine kinases. Our data provide evidence
that p140Cap is the substrate for the Abl kinase. Abl is an
ubiquitous tyrosine kinase that controls actin remodelling, cell
motility and adhesion, and is involved in cell differentiation
processes through association with specific substrates, most of
which mediate signal transduction and cytoskeleton dynamics
[23,24]. Indeed in silico analysis coupled to in vitro kinase assays
with recombinant tyrosine kinases allowed the identification of Abl
Figure 4. p140Cap tyrosine phosphorylation on EPLYA and EGLYA sequences regulate Csk binding. A. cDNAs encoding GFP, GFP-
p140Cap full length (p140 WT) and its double mutant (p140 EPLY/FA, EGLY/FA) were used to transfect HEK-293 cells. Cells were treated with 100
micromolar pervanadate solution as in Figure 2B and extracts were immunoprecipitated with a specific antibody to p140Cap and analysed by
western blotting using monoclonal antibodies PY99, p140Cap, and Csk. The results are representative of six independent experiments. B. HEK-293
cells transfected as in A for 48 hours, were starved overnight and treated for 0, 5, 15 minutes with 20%FBS. Cell extracts were immunoprecipitated
with a specific antibody to p140Cap. Immunocomplexes were analysed by western blotting using monoclonal antibodies specific for
phosphotyrosines, p140Cap, Csk and Vinculin.
doi:10.1371/journal.pone.0054931.g004
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Figure 5. Identification of Abl as the tyrosine kinase responsible of p140Cap tyrosine phosphorylation on EPLYA and EGLYA
sequences. A–B. For each recombinant kinase, bar charts of the mean values of the triplicate activity raw counts of kinase activity and the means of
the corresponding background values of the synthetic peptides with (black bars) or without (white bars) enzyme are indicated. The synthetic
peptides contain respectively EPLYA (A) and EGLYA (B) sequences. A. cDNAs encoding GFP and GFP-p140Cap full length (p140 WT) were used to
transfect HEK-293 cells. After 24 hours, cells were starved and treated with 10 micromolar Src inhibitor SU6656 or Abl inhibitor Imatinib for 16 hours.
Cell extracts were immunoprecipitated with a specific antibody to p140Cap and analysed by western blotting using monoclonal antibodies for
phosphotyrosine and p140Cap. B. Left panel. cDNAs encoding GFP, GFP-p140Cap full length (p140 WT) and its double mutant (p140 EPLY/FA, EGLY/
FA) were used to transfect HEK-293 cells together with cDNA encoding for active BCR-Abl. Extracts were immunoprecipitated with a specific antibody
to p140Cap and analysed by western blotting using monoclonal antibodies to phosphotyrosines (PY99) and p140Cap. Right panel. cDNAs encoding
GFP, GFP-p140Cap full length (p140 WT) and its double mutant (p140 EPLY/FA, EGLY/FA) were used to transfect HEK-293 cells. Cells were treated with
100 micromolar pervanadate solution for five minutes and extracts were processed as in the left panel.
doi:10.1371/journal.pone.0054931.g005
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as the major kinase involved in tyrosine phosphorylation of
EPLYA and EGLYA synthetic peptides. Consistently, in HEK-
293 cells, the specific Abl inhibitor Imatinib strongly reduces
p140Cap tyrosine phosphorylation. Moreover, in the same cellular
system, tyrosine phosphorylation triggered by the constitutive
active BCR-Abl kinase was heavily reduced on the double
p140Cap mutant (EPLY/FA, EGLY/FA). ABL specificity for a
given substrate is conferred by both target sequence and domain-
guided protein-protein interactions. Notably, the EPLYA and
EGLYA sequences fit well with the Abl target site consensus
sequence [23]. In particular, they contain aliphatic amino acids (L)
at position –1, as well as acidic residues (E) at positions –3, thus
ascribing p140Cap as a new Abl kinase substrate. Interestingly,
our data are further supported by recent reports showing that Abl
is involved in EPIYA repeats phosphorylation in different CagA
strains infected cells and that phosphorylation of these sites
controls cell elongation upon CagA infection [29,30].
In conclusion, we identified serine and tyrosine phosphorylated
residues on the human p140Cap adaptor in breast cancer cells.
Moreover we validated two tyrosine residues inserted in the
EGLYA and EPLYA sequences as the major phosphorylated sites
responsible for p140Cap tyrosine phosphorylation and Csk kinase
binding. We also found that p140Cap phosphorylation on the
EPLYA and EGLYA sequences in HEK-293 cells is dependent on
the Abl tyrosine kinase activity. Overall, elucidating the role of the
EGLYA and ELPYA sequences in p140Cap may give further
insights into the mechanisms underlying p140Cap biological
activity in both physiological and pathological conditions.
Supporting Information
Figure S1 Expression of p140Cap EPLYA/EGLYA dou-
ble mutant partially rescues Src activation. cDNAs
encoding GFP, GFP-p140Cap WT and GFP-p140Cap EPLYA/
EGLYA double mutant were used to transfect HEK-293 cells.
After 48 hours, cells were starved overnight and treated with 20%
FBS for the indicated times. Cell extracts were western blotted
using polyclonal antibodies to p140Cap, active Src (pY416) and
total Src. The results are representative of two independent
experiments. Numbers express the quantification of the ratio
between active Src and total Src, with 100 as arbitrary value
assigned to the levels of Src phosphorylation in GFP-transfected
cells.
(PSD)
Figure S2 Abl silencing in HEK-293 cells causes down-
regulation of p140Cap tyrosine phosphorylation. cDNA
encoding GFP-p140Cap WT was used to transfect HEK-293 cells
together with Abl shRNA construct G10. After 48 hours, cell
extracts were immunoprecipitated with a specific antibody to
p140Cap and analysed by western blotting using monoclonal
antibodies to phosphotyrosine PY99 and p140Cap. Abl silencing
was evaluated on cell extracts. The results are representative of
two independent experiments.
(PSD)
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